Clinical Trials
8 trialsNCT07100080 2026-05-27
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT06712316 2026-05-22
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
BioNTech SE
Phase 2/3 Recruiting
NCT07005102 2026-05-22
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
Phase 2/3 Recruiting
NCT07365319 2026-05-20
TeLuRide-008
Eikon Therapeutics
Phase 2/3 Recruiting
NCT07063745 2026-05-18
MountainTAP-29
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT06236438 2026-02-23
LIVIGNO-4
AbbVie
Phase 2/3 Recruiting
NCT07131319 2026-02-02
SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
Second Affiliated Hospital of Nanchang University
Phase 2/3 Recruiting
NCT05255302 2025-04-01
DIAL
Intergroupe Francophone de Cancerologie Thoracique
Phase 2/3 Recruiting